En Carta Diagnostics vs Freenome
En Carta Diagnostics vs Freenome, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: En Carta Diagnostics is on 52/100 and Freenome on 59/100.
Where each one leads
En Carta Diagnostics
Leads on none of the measures we hold for both companies.
Freenome
- our overall score: 59/100 against 52/100
- domain rating: 56/100 against 0/100
- headcount: 402 against 12
- funding raised: $570M against $5.0M
- LinkedIn following: 46,860 against 2,091
At a glance
| Measure | En Carta Diagnostics | Freenome |
|---|---|---|
| What it is | Developing a new generation of molecular diagnostics for at-home use, combining laboratory accuracy with rapid test simplicity. | Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology. |
| Category | Biotechnology, HealthTech, Diagnostics, Medical Devices | Biotechnology, Healthcare, Artificial Intelligence, Biotech |
| Sells toBusiness model | B2B2C | B2B |
| Offering | Hardware | Services |
| Founded | 2022 | 2014 |
| Headquarters | Paris, France | South San Francisco, USA |
| Status | Inactive | Active |
Size, funding and growth
| Measure | En Carta Diagnostics | Freenome |
|---|---|---|
| Employees | 12 | 402 |
| Total funding | $5.0M | $570M |
| Latest round | Seed | Series D |
| Valuation | Not published | $1.1B |
| LinkedIn followers | 2,091 | 46,860 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | En Carta Diagnostics | Freenome |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 52/100 | 59/100 |
| Traction | 45/100 | 60/100 |
| Team | 70/100 | Not published |
| Search visibility | 20/100 | 31/100 |
| Quality | 58/100 | 78/100 |
| Agent readinessHow well an AI agent can read and act on the site | Not published | D (46/100) |
| Domain ratingLink authority, 0-100 | 0/100 | 56/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | En Carta Diagnostics | Freenome |
|---|---|---|
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Tag Manager |
| Support stack | Not detected | HubSpot |
En Carta Diagnostics vs Freenome: common questions
Which is better, En Carta Diagnostics or Freenome?
On our 0-100 score Freenome rates higher (59/100 against 52/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do En Carta Diagnostics and Freenome compare on the numbers?
Freenome leads on our overall score (59/100 against 52/100), domain rating (56/100 against 0/100), headcount (402 against 12), funding raised ($570M against $5.0M), LinkedIn following (46,860 against 2,091).
Read the full En Carta Diagnostics review and pricing or the Freenome review and pricing. You can also browse other En Carta Diagnostics alternatives we track.